Table 2 Medications after enrollment

 GCs

23 (72)

89 (70)

0.817

   <5 mg/day

1 (3)

3 (2)

0.821

   ≥5, ≤10 mg/day

19 (59)

81 (63)

0.715

   >10, ≤20 mg/day

2 (6)

4 (3)

0.462

   >20 mg/day

1 (3)

1 (1)

0.357

 MTX

28 (87)

121 (95)

0.217

   ≤10 mg/week

21 (66)

79 (62)

0.715

  >10, ≤15 mg/week

6 (19)

40 (31)

0.217

   >15 mg/week

1 (3)

2 (2)

0.606

 LEF

5 (16)

107 (84)

<0.001

 SSZ

14 (44)

2 (2)

<0.001

 HCQ

24 (75)

14 (11)

<0.001

 CysA

4 (13)

4 (3)

0.062

 Iguratimod

1 (3)

10 (8)

0.415

 Biologic agents

6 (19)

38 (30)

0.273

  Tocilizumab

4 (13)

30 (23)

0.234

  Yi Sai Pu

2 (6)

5 (4)

0.606

  Infliximab

0 (0)

3 (2)

NA

 GCs

900 (0–1406)

1069 (0–1556)

0.506

 MTX

260 (201–315)

288 (260–348)

0.024

 LEF

0 (0–0)

1800 (1500–3263)

<0.001

 SSZ

0 (0–270,000)

0 (0–0)

<0.001

 HCQ

54,000 (3000–72,000)

0 (0–0)

<0.001

 CysA^c

0 (0–19,515)

0 (0–4500)

0.020

 Iguratimod^c

0 (0–2625)

0 (0–9000)

0.330

 Tocilizumab^c

0 (0–1880)

0 (0–2400)

0.218

 Yi Sai Pu^c

0 (0–600)

0 (0–0)

0.606

 Infliximab^c

0 (0–0)

0 (0–0)

NA

 GCs

1800 (0–2790)

1744 (0–2475)

0.418

 MTX

520 (413–650)

585 (520–715)

0.023

 LEF

0 (0–0)

3600 (2719–6600)

<0.001

 SSZ

68,000 (0–536,000)

0 (0–0)

<0.001

 HCQ

90,000 (3000–144,000)

0 (0–0)

<0.001

 CysA^c

0 (0–37,575)

0 (0–12,825)

0.016

 Iguratimod^c

0 (0–5775)

0 (0–9000)

0.393

 Tocilizumab^c

0 (0–1880)

0 (0–2800)

0.184

 Yi Sai Pu^c

0 (0–600)

0 (0–0)

0.606

 Infliximab^c

0 (0–0)

0 (0–0)

NA